Daiichi Sankyo

Corporate brand

Japanese multinational pharmaceutical company focused on innovative medicines, with particular strength in oncology and antibody-drug conjugates.

Last updated October 18, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Daiichi Sankyo is a Japanese multinational pharmaceutical company headquartered in Tokyo. The company was created in 2005 through the merger of Daiichi Pharmaceutical and Sankyo, two long-established Japanese drugmakers whose histories extend back to the late nineteenth and early twentieth centuries. The merger combined Daiichi’s prescription-medicine business with Sankyo’s research, commercial, and international capabilities and created a company intended to compete more effectively in an increasingly global pharmaceutical industry. The company researches, develops, manufactures, and commercializes prescription medicines. Its principal therapeutic interests have included oncology, cardiovascular disease, infectious diseases, and selected specialty areas. In recent years, oncology has become the central pillar of Daiichi Sankyo’s corporate strategy. The company is especially associated with antibody-drug conjugates (ADCs), medicines that link a tumor-targeting antibody to a cytotoxic payload. Its ADC platform has generated a portfolio of products and partnerships that substantially raised the company’s profile in global biopharmaceutical markets. Daiichi Sankyo’s best-known modern product is Enhertu, an HER2-directed ADC developed jointly with AstraZeneca. Enhertu has been studied and approved in several HER2-expressing cancers, with indications varying by jurisdiction and over time. The product is commercially important to both companies and illustrates Daiichi Sankyo’s strategy of combining proprietary drug-conjugate technology with large-scale international development and commercialization capabilities. Other oncology assets include datopotamab deruxtecan, developed with AstraZeneca, and patritumab deruxtecan, which has been developed in collaboration with Merck in selected research and development activities. The company has also advanced additional deruxtecan-based ADC candidates against different molecular targets. Outside oncology, Daiichi Sankyo is known for Lixiana/Savaysa, the anticoagulant edoxaban, and for a broader portfolio covering cardiovascular and other prescription indications. Product availability, brand names, labels, and commercial rights differ among countries. The company has also maintained manufacturing and commercial operations through subsidiaries and regional organizations, including a substantial presence in the United States and Europe. Daiichi Sankyo is a publicly traded company on the Tokyo Stock Exchange. It operates as an independent pharmaceutical group rather than as a consumer-health or generic-drug retailer. Its present positioning is that of an innovation-led biopharmaceutical company, with oncology and ADC technology at the core of its growth strategy. The company’s history also includes periods of portfolio restructuring, research prioritization, alliances, and the discontinuation or deprioritization of selected development programs. These decisions reflect the high scientific, clinical, regulatory, and commercial risks inherent in pharmaceutical research. The Daiichi Sankyo name therefore represents both the corporate group and a global medicines brand. Its identity is rooted in Japanese pharmaceutical history, while its current business model depends on multinational clinical development, regulatory submissions, strategic partnerships, and sales in major medicine markets.

History

Daiichi Sankyo was established in 2005 through the merger of Daiichi Pharmaceutical Co., Ltd. and Sankyo Co., Ltd. The transaction brought together two Japanese pharmaceutical businesses with different but complementary histories. Sankyo traced its origins to a company founded in 1899 by Takamine Jokichi and developed from a Japanese chemical and pharmaceutical enterprise into an established medicines manufacturer. Daiichi Pharmaceutical originated in the early twentieth century and became known for prescription medicines and pharmaceutical research. The merger created a larger platform for research, manufacturing, commercialization, and international expansion. Following its formation, Daiichi Sankyo operated across a range of therapeutic areas, including cardiovascular medicine, anti-infectives, oncology, and other prescription categories. Its strategy included both internal research and external partnerships. As the pharmaceutical industry became more dependent on large clinical trials, global regulatory capabilities, and specialized technologies, the company sought to strengthen its presence outside Japan while maintaining its domestic base. A significant part of the company’s later history involved the development of antibody-drug conjugates. Daiichi Sankyo’s deruxtecan technology uses an antibody to recognize a molecular target and a cleavable linker to deliver a cytotoxic payload to cancer cells. This platform became the foundation for a series of oncology candidates. The most prominent result was trastuzumab deruxtecan, known commercially as Enhertu, which Daiichi Sankyo developed with AstraZeneca. The collaboration combined Daiichi Sankyo’s ADC research and technology with AstraZeneca’s global development and commercial resources. Clinical and regulatory progress in HER2-expressing breast, gastric, lung, and other cancers helped make Enhertu the company’s signature global product. Daiichi Sankyo also expanded its oncology pipeline through additional ADC programs. Datopotamab deruxtecan targets TROP2 and has been developed with AstraZeneca, while patritumab deruxtecan targets HER3 and has been developed through collaborations involving Merck. Other candidates have targeted different tumor antigens. The expansion of this pipeline changed the company’s public identity from that of a diversified Japanese pharmaceutical company to that of a globally visible oncology and ADC specialist. The company has continued to maintain important non-oncology products. Edoxaban, an oral factor Xa inhibitor marketed as Lixiana in many markets and Savaysa in the United States, is a major cardiovascular medicine. Daiichi Sankyo has also operated through regional subsidiaries and commercial organizations in North America, Europe, and other markets. Product rights and labels have varied according to local regulatory approvals and partnership arrangements. Like other research-based drugmakers, Daiichi Sankyo has made portfolio decisions in response to clinical results, safety considerations, regulatory requirements, competitive conditions, and resource allocation. Some programs have been advanced, partnered, delayed, or discontinued. The company’s modern strategy has increasingly prioritized oncology and platform technologies capable of producing multiple medicines rather than relying equally on every historical therapeutic area. Today, Daiichi Sankyo remains a publicly listed Japanese pharmaceutical group with global operations. Its principal strategic narrative is built around innovative medicines, oncology, and ADC technology, while its established cardiovascular portfolio continues to contribute to the business. The group’s development model combines internal science with major pharmaceutical partnerships and multinational clinical execution.

2019
Enhertu is approved in Japan
[5]Daiichi Sankyo news and press releasesdaiichisankyo.com
Japan approves trastuzumab deruxtecan, later marketed globally as Enhertu, for a HER2-positive breast-cancer indication.
2019
Global Enhertu collaboration expands
[6]AstraZeneca media centreastrazeneca.com
Daiichi Sankyo and AstraZeneca continue joint global development and commercialization of trastuzumab deruxtecan.
2011
Edoxaban receives Japanese approval
[4]Daiichi Sankyo productsdaiichisankyo.com
Edoxaban is approved in Japan for prevention of venous thromboembolism associated with orthopedic surgery; later approvals and indications expand internationally.
2005
Daiichi Sankyo is formed
[2]Daiichi Sankyo company historydaiichisankyo.com
Daiichi Pharmaceutical and Sankyo merge to create Daiichi Sankyo Co., Ltd.
1899
Sankyo predecessor is established
[2]Daiichi Sankyo company historydaiichisankyo.com
Sankyo traces its corporate history to a pharmaceutical and chemical business established in Japan in 1899.

Products and positioning

An innovation-focused multinational pharmaceutical company whose current strategic identity is centered on oncology, antibody-drug conjugates, and globally developed prescription medicines.

Oncology; antibody-drug conjugate · 2019
Enhertu
Enhertu is trastuzumab deruxtecan, a HER2-directed antibody-drug conjugate discovered and developed by Daiichi Sankyo with AstraZeneca. It is designed to deliver a topoisomerase I inhibitor payload to cells expressing HER2. Approvals and indications vary by country and have expanded across several HER2-expressing solid tumors.
Cardiovascular medicine; anticoagulant · 2011
Lixiana/Savaysa
Lixiana, marketed as Savaysa in the United States, is edoxaban, an oral factor Xa inhibitor. It is used for approved indications including prevention of stroke and systemic embolism in appropriate patients with non-valvular atrial fibrillation and treatment or prevention of venous thromboembolism, subject to local labeling.
Oncology; antibody-drug conjugate
Datopotamab deruxtecan
Datopotamab deruxtecan is a TROP2-directed antibody-drug conjugate developed by Daiichi Sankyo and AstraZeneca. It is intended for treatment of selected solid tumors and has been evaluated in multiple late-stage clinical programs. Regulatory outcomes and approved uses depend on jurisdiction.
Oncology; antibody-drug conjugate
Patritumab deruxtecan
Patritumab deruxtecan is an investigational HER3-directed antibody-drug conjugate. Daiichi Sankyo has studied it in solid tumors, including previously treated EGFR-mutated non-small-cell lung cancer, through development and collaboration arrangements. It is not treated here as an approved product because authorization varies and its development status has changed over time.

Controversies

2019
Daiichi Sankyo files declaratory judgment action against Seattle Genetics
Daiichi Sankyo filed a declaratory judgment action in the District Court of Delaware in a dispute with Seattle Genetics over rights to linker technology used in antibody-drug conjugates, including DS-8201. Seattle Genetics said Daiichi's filing circumvented the dispute-resolution process in their former agreement; both parties disputed the other's claims to the technology.
Source

Enhertu oncology education and awareness
International
Daiichi Sankyo and its partners have supported scientific education, clinical-data communication, and disease-awareness activity surrounding HER2 testing and the use of Enhertu in approved oncology settings.
Outcome. The activity has accompanied the expansion of clinical evidence and regulatory indications; a single consolidated consumer campaign outcome is not publicly established.
Source

Brand decisions

2019
Launch trastuzumab deruxtecanProduct launch
Background
Clinical results supported development of a HER2-directed antibody-drug conjugate for patients with HER2-positive breast cancer.
Action taken
Daiichi Sankyo launched trastuzumab deruxtecan in Japan and developed it globally with AstraZeneca under the Enhertu brand.
Aftermath
The product became the foundation of Daiichi Sankyo’s global oncology strategy and ADC leadership position.
Source
2015
Prioritize oncology and innovative medicinesStrategy
Background
Daiichi Sankyo increasingly emphasized high-value innovative medicines and its emerging antibody-drug conjugate platform.
Action taken
The company directed greater research and development attention toward oncology and platform-based ADC programs while continuing selected cardiovascular and other businesses.
Aftermath
Oncology became the central strategic growth area and Enhertu became the company’s leading global medicine.
Source
2005
Merge Daiichi Pharmaceutical and SankyoM&A
Background
The two Japanese pharmaceutical companies sought greater scale and a stronger platform for research, international operations, and commercialization.
Action taken
They combined their businesses and established Daiichi Sankyo as a new pharmaceutical group.
Aftermath
The merger created the corporate structure that continues to operate under the Daiichi Sankyo name.
Source

Recent events

Unconfirmed
AstraZeneca and Daiichi Sankyo partner with Summit to test cancer drug combination[10]阿斯利康与第一三共携手Summit测试癌症药物联合疗法news.google.com
Reported: 2026-10-02
AstraZeneca and Daiichi Sankyo have partnered with Summit to test a cancer drug combination, as reported by Reuters.
Unconfirmed
Daiichi Sankyo ifinatamab filing withdrawal[11]第一三共ifinatamab申报撤回news.google.com
Reported: 2026-10-01
A Yahoo Finance article headline attributes an ifinatamab filing withdrawal to Daiichi Sankyo Company (TSE:4568) and uses it as the news peg for a valuation piece asking whether the company is undervalued. The supplied evidence is the headline only and does not specify the regulator, market, or date of the withdrawal.
Unconfirmed
Daiichi Sankyo reportedly carries out layoffs[12]第一三共据报正在裁员industry.caijing.com.cn
The article reports that Daiichi Sankyo was carrying out layoffs affecting its anti-infective and respiratory analgesic product lines, with affected employees mainly outside Beijing, Shanghai and Guangzhou.
2021-01-27
ENHERTU receives Japan Techno-Economics Society Prime Minister's Award[13]ENHERTU获得日本技术经济学会首相奖finanznachrichten.de
Reported: 2021-01-27
Daiichi Sankyo announced that ENHERTU received the Prime Minister's Award at the 9th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society.
2020-05-26
Daiichi Sankyo launches ENHERTU in Japan[14]第一三共在日本推出ENHERTUfinanznachrichten.de
Reported: 2020-05-26
Daiichi Sankyo announced the launch of ENHERTU (trastuzumab deruxtecan) in Japan for patients with HER2-positive unresectable or recurrent breast cancer after prior chemotherapy, subject to the stated treatment limitations.
2019-11-05
Daiichi Sankyo files declaratory judgment action against Seattle Genetics[9]Daiichi Sankyo files declaratory judgment action against Seattle Geneticsfiercebiotech.com
Reported: 2019-11-05
Daiichi Sankyo filed a declaratory judgment action in the District Court of Delaware in a dispute with Seattle Genetics over rights to linker technology used in antibody-drug conjugates, including DS-8201. Seattle Genetics said Daiichi’s filing circumvented the dispute-resolution process in their former agreement; both parties disputed the other’s claims to the technology.

Sources15 sources

Cite this profile: Cite the canonical profile. /brand-wiki/第一三共 · Editorial policy · How profiles are compiled